Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Odronextamab + Lenalidomide vs Rituximab + Lenalidomide in R/R FL and MZL (OLYMPIA-5)
NCT06149286Phase 3Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Dec 2023
- Primary completion
- Apr 2031
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 3 trial of odronextamab in follicular lymphoma (FL), marginal zone lymphoma (MZL), sponsored by Regeneron Pharmaceuticals. Started Dec 2023; status: recruiting.
02
Drugs
odronextamab
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT06149286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06149286.